Enrollment per centre N112

1
Daily Temozolomide Following Failure of Prior RT
TMZ for GBM Update on the RESCUE Study J.
Perry, W. Mason, K. Belanger, P. Kavan, D.
Fulton, J. Easaw, S. Kirby, D. MacDonald, C.
Shields and J.-F. Pouliot
2
42-year-old woman with GBM treated with daily
temozolomide at first relapse on the
NCIC-CTG/EORTC Trial
PD 9 mo after RT/TMZ, 6 cycles adjuvant TMZ
CR after 4 cycles continuous TMZ 50 mg/m2
3
Temozolomide Dose-intense Rescue
4
RESCUE Study Design
5
Study Objectives
6
Main Inclusion Criteria
7
Main Exclusion Criteria
8
(No Transcript)
9
Demographics
10
Six-month Progression-free Survival
11
Progression-free Survival (by subgroup)
12
Non hematological Toxicity (worst grade)
All AEs irrespective of causality incidence
gt2 No Grade 4 toxicity reported at this point in
time
13
Hematological Toxicity(worsened grade since
baseline)
14
Baseline Hematological Abnormalities(all
patients)
15
Conclusions